Nabriva Therapeutics Stock Price

0.01 (0.87%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Nabriva Therapeutics PLC NBRV NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.87% 1.16 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.14 1.12 1.18 1.15 1.15
Bid Price Ask Price Spread News
1.14 1.16 0.02 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,289 952,918 $ 1.15 $ 1,097,446 - 1.00 - 6.188
Last Trade Time Type Quantity Stock Price Currency
19:59:14 1 $ 1.16 USD


Draw Mode:

Nabriva Therapeutics PLC Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 57.70M 49.74M 49.65M $ 2.86M $ - -5.74 -0.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 15.22k 0.70%

more financials information »

Nabriva Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NBRV Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.,0000.043.57%
1 Month1.021.181.0051.10781,7460.1413.73%
3 Months1.381.411.001.151,024,059-0.22-15.94%
6 Months2.03582.331.001.472,554,094-0.8758-43.02%
1 Year5.806.1881.002.292,170,290-4.64-80.0%
3 Years26.1032.701.008.792,173,130-24.94-95.56%
5 Years74.40141.001.0012.841,427,554-73.24-98.44%

Nabriva Therapeutics Description

Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections.

Your Recent History
Nabriva Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.